TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics Statistics

Total Valuation

TCRX has a market cap or net worth of $212.41 million. The enterprise value is $39.12 million.

Market Cap	212.41M
Enterprise Value	39.12M

Important Dates

The last earnings date was Tuesday, November 12, 2024, before market open.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

TCRX has 53.37 million shares outstanding. The number of shares has increased by 11.57% in one year.

Current Share Class	49.09M
Shares Outstanding	53.37M
Shares Change (YoY)	+11.57%
Shares Change (QoQ)	+0.80%
Owned by Insiders (%)	0.81%
Owned by Institutions (%)	58.98%
Float	31.30M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.48
Forward PS	29.51
PB Ratio	0.96
P/TBV Ratio	0.96
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.56, with a Debt / Equity ratio of 0.39.

Current Ratio	9.56
Quick Ratio	9.46
Debt / Equity	0.39
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-32.11

Financial Efficiency

Return on equity (ROE) is -55.92% and return on invested capital (ROIC) is -25.95%.

Return on Equity (ROE)	-55.92%
Return on Assets (ROA)	-23.35%
Return on Capital (ROIC)	-25.95%
Revenue Per Employee	$60,792
Profits Per Employee	-$722,747
Employee Count	154
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.99% in the last 52 weeks. The beta is 0.78, so TCRX's price volatility has been lower than the market average.

Beta (5Y)	0.78
52-Week Price Change	-22.99%
50-Day Moving Average	5.21
200-Day Moving Average	6.60
Relative Strength Index (RSI)	30.92
Average Volume (20 Days)	263,403

Short Selling Information

The latest short interest is 2.16 million, so 4.06% of the outstanding shares have been sold short.

Short Interest	2.16M
Short Previous Month	2.24M
Short % of Shares Out	4.06%
Short % of Float	6.92%
Short Ratio (days to cover)	11.66

Income Statement

In the last 12 months, TCRX had revenue of $9.36 million and -$111.30 million in losses. Loss per share was -$2.09.

Revenue	9.36M
Gross Profit	-91.04M
Operating Income	-119.47M
Pretax Income	-96.80M
Net Income	-111.30M
EBITDA	-114.79M
EBIT	-119.47M
Loss Per Share	-$2.09

Balance Sheet

The company has $271.12 million in cash and $90.36 million in debt, giving a net cash position of $180.76 million or $3.39 per share.

Cash & Cash Equivalents	271.12M
Total Debt	90.36M
Net Cash	180.76M
Net Cash Per Share	$3.39
Equity (Book Value)	229.09M
Book Value Per Share	4.29
Working Capital	245.43M

Cash Flow

In the last 12 months, operating cash flow was -$107.18 million and capital expenditures -$3.41 million, giving a free cash flow of -$110.58 million.

Operating Cash Flow	-107.18M
Capital Expenditures	-3.41M
Free Cash Flow	-110.58M
FCF Per Share	-$2.07

Margins

Gross Margin	n/a
Operating Margin	-1,276.07%
Pretax Margin	-1,188.88%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-472.93%

Dividends & Yields

TCRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.57%
Shareholder Yield	-11.57%
Earnings Yield	-50.62%
FCF Yield	-50.29%

Analyst Forecast

The average price target for TCRX is $11.40, which is 186.43% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.40
Price Target Difference	186.43%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	26.22%
EPS Growth Forecast (5Y)	-8.00%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TCRX has an Altman Z-Score of -0.06 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.06
Piotroski F-Score	2